Eseroline

In the article that we present below, we want to delve into the fascinating world of Eseroline. Along these lines, we will explore its origins, its evolution over time and its importance in today's society. Eseroline has been the subject of debate and study by experts from various disciplines, who have provided valuable knowledge that allows us to better understand its influence on our lives. Through this article, we invite you to reflect on Eseroline and discover aspects that you may not have known about this topic.

Eseroline
Skeletal formula
Ball-and-stick model
Clinical data
Other namesEseroline
ATC code
  • none
Identifiers
  • (3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrroloindol-7-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H18N2O
Molar mass218.300 g·mol−1
3D model (JSmol)
  • C12CCN(1N(C3=C2C=C(C=C3)O)C)C
  • InChI=1S/C13H18N2O/c1-13-6-7-14(2)12(13)15(3)11-5-4-9(16)8-10(11)13/h4-5,8,12,16H,6-7H2,1-3H3/t12-,13+/m1/s1
  • Key:HKGWQUVGHPDEBZ-OLZOCXBDSA-N
  (verify)

Eseroline is a drug which acts as an opioid agonist. It is a metabolite of the acetylcholinesterase inhibitor physostigmine but unlike physostigmine, the acetylcholinesterase inhibition produced by eseroline is weak and easily reversible, and it produces fairly potent analgesic effects mediated through the μ-opioid receptor. This mixture of activities gives eseroline an unusual pharmacological profile, although its uses are limited by side effects such as respiratory depression and neurotoxicity.

References

  1. ^ Fürst S, Friedmann T, Bartolini A, Bartolini R, Aiello-Malmberg P, Galli A, et al. (September 1982). "Direct evidence that eseroline possesses morphine-like effects". European Journal of Pharmacology. 83 (3–4): 233–41. doi:10.1016/0014-2999(82)90256-4. PMID 6293841.
  2. ^ Jhamandas K, Elliott J, Sutak M (March 1981). "Opiatelike actions of eseroline, an eserine derivative". Canadian Journal of Physiology and Pharmacology. 59 (3): 307–10. doi:10.1139/y81-048. PMID 7194726.
  3. ^ Galli A, Renzi G, Grazzini E, Bartolini R, Aiello-Malmberg P, Bartolini A (April 1982). "Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine". Biochemical Pharmacology. 31 (7): 1233–8. doi:10.1016/0006-2952(82)90009-0. PMID 7092918.
  4. ^ Agresti A, Buffoni F, Kaufman JJ, Petrongolo C (November 1980). "Structure--activity relationships of eseroline and morphine: ab initio quantum-chemical study of the electrostatic potential and of the interaction energy with water". Molecular Pharmacology. 18 (3): 461–7. PMID 7464812.
  5. ^ Galli A, Ranaudo E, Giannini L, Costagli C (November 1996). "Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences". The Journal of Pharmacy and Pharmacology. 48 (11): 1164–8. doi:10.1111/j.2042-7158.1996.tb03914.x. PMID 8961166. S2CID 45395195.
  6. ^ Liu WF (April 1991). "Effect of eseroline on schedule-controlled behavior in the rat". Pharmacology, Biochemistry, and Behavior. 38 (4): 747–51. doi:10.1016/0091-3057(91)90236-U. PMID 1871191. S2CID 12857298.
  7. ^ Berkenbosch A, Rupreht J, DeGoede J, Olievier CN, Wolsink JG (February 1993). "Effects of eseroline on the ventilatory response to CO2". European Journal of Pharmacology. 232 (1): 21–8. doi:10.1016/0014-2999(93)90723-U. PMID 8458393.
  8. ^ Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.


Stub icon

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia